Canakinumab (Synonyms: Ilaris; ACZ 885) |
| رقم الكتالوجGC66328 |
كاناكينوماب (ACZ885) هو مضاد بشري مؤتلف لـ IL-1β ؛ الأجسام المضادة أحادية المنشأ. يُظهر Canakinumab قيم IC50 البالغة 43.6 و 40.8 pM للإنسان و marmoset IL-1β ؛ على التوالي. يعتمد أسلوب عمل كانكينيوماب على تحييد IL-1β ؛ الإشارات ، مما يؤدي إلى قمع الالتهاب المرتبط باضطرابات المناعة الذاتية.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 914613-48-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 43.6 pM (human IL-1β), 40.8 pM (marmoset IL-1β)[2]
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2].
Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β[2].Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1b[2].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *